Idhifa

Warnings and Precautions for Idhifa

Boxed Warning — Idhifa: Idhifa can cause differentiation syndrome, which can be fatal if not treated. Symptoms may include fever, difficulty breathing, acute respiratory distress, pulmonary infiltrates, pleural or pericardial effusions, rapid weight gain, peripheral edema, and hepatic, renal, or multi-organ dysfunction. If differentiation syndrome is suspected, treat promptly with corticosteroids and hemodynamic monitoring.

Differentiation Syndrome

Can occur as early as 1 day and up to 5 months after starting Idhifa. Requires prompt corticosteroid treatment at the first suspicion of symptoms.

Hepatotoxicity

Monitor liver function tests before starting and during the first 3 months of treatment.

Tumor Lysis Syndrome

Monitor patients at risk and manage promptly if it occurs.

Embryo-Fetal Toxicity

Idhifa can cause fetal harm. Advise patients of reproductive potential to use effective contraception during treatment and for 1 month after the final dose.

• Monitor closely for signs of differentiation syndrome, especially during the first 3 months of treatment.
• Regular liver function and blood count monitoring is required throughout treatment.
• Report fever, breathing difficulty, or rapid weight gain to the treating physician immediately.

How to Access Idhifa in India: A 6-Step Process

Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.

Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.

Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.

Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.

Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.

Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.

Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.

Documentation and Availability of Idhifa

Idhifa (enasidenib) received FDA approval in August 2017 and is marketed by Celgene Corporation, a Bristol Myers Squibb company.

Documentation Required

Import of Idhifa through a Named Patient Program requires a valid prescription from the treating hematologist-oncologist, confirmation of IDH2 mutation status via an FDA-approved companion diagnostic test, and supporting clinical documentation as required by Indian regulatory authorities.

Sourcing

NPP sources Idhifa directly from Bristol Myers Squibb's authorized supply chain to ensure product authenticity and regulatory compliance.

Sourcing and Delivery of Idhifa

Idhifa is sourced through verified, GDP-compliant channels from its authorized supply chain to ensure authenticity and quality.

Storage Requirements

Idhifa tablets should be stored at 20°C to 25°C (68°F to 77°F), with the container kept tightly closed with its desiccant canister inside to protect from moisture.

Delivery Process

Once sourced, Idhifa is packed and transported under appropriate temperature-controlled conditions to preserve product integrity throughout the import process, with tracking and updates provided at each stage of delivery to the patient or treating hospital in India.

Availability of Idhifa Across Major Cities in India

Patients across India can access Idhifa through NPP's regulated import pathway, with hematology-oncology specialists in major cities supporting the treatment process.

Mumbai

Leading hematology-oncology centers in Mumbai support IDH2 mutation testing and treatment coordination for Idhifa access.

Delhi

Delhi's major cancer hospitals assist patients with molecular testing and prescription support for Idhifa.

Bangalore

Bangalore's oncology network offers access to IDH2 testing and treatment planning for eligible AML patients.

Chennai

Chennai-based specialists coordinate Idhifa access alongside comprehensive AML care.

Hyderabad

Hyderabad's cancer care institutions support patients pursuing Idhifa therapy following confirmed IDH2 mutation status.

Kolkata

Kolkata's oncology centers help coordinate documentation and treatment access for Idhifa.

Pune

Pune-based hematologists assist with IDH2 mutation testing and Idhifa treatment planning.

Ahmedabad

Ahmedabad's specialty hospitals support the import and treatment process for Idhifa.

Kochi

Kochi's oncology units assist patients with the documentation needed for Idhifa access.

Chandigarh

Chandigarh's cancer care centers support Idhifa treatment coordination for patients from North India.

Jaipur

Jaipur's oncology specialists help patients navigate the Idhifa access process.

Lucknow

Lucknow-based cancer centers assist patients pursuing Idhifa therapy.

Bhubaneswar

Bhubaneswar's oncology institutions support access to Idhifa for eligible patients.

Guwahati

Guwahati's specialists help coordinate Idhifa access for patients across the Northeast.

Patients in other cities across India can also access Idhifa through NPP's nationwide coordination network.